Hypertension Pharmacology Flashcards
Targets of antihypertensive therapy
- fluid balance (sodium & water)
- renin angiotensin system (RAS)
- central & peripheral control of SNS
- tone of vascular smooth muscle
Classes of antihypertensive drugs
- Diuretics
- RAS blockers
- Ca+ channel blockers
- Sympatholytics
- Vasodilators
Diuretics: initial & long term use
- initial use: decrease extracellular fluid volume and CO
- long term use: decrease vascular resistance; decreased response of VSM to vasoconstrictors, impaired release of NE/Epi
- cellular mechanism: decrease in VSM Na+ & secondarily decrease in Ca2+
Diuretics: major use & adverse effects
- use: alone of in combination, use in treatment of heart failure
- adverse effects: most deplete K+ (except for K+ sparing diuretics)
Thiazide diuretics
- chlorothiazide & hydrochlorothiazide
- mechanism: block Na+Cl- symporter in distal convoluted tubule
- effect: moderate diuresis, reduced by NSAIDs
- adverse effects: hypkalemia, decreased uric acid & calcium excretion, thiazides & sulfonamides cross reactivity
High ceiling LOOP diuretics
- furosemide, bumetanide, torsemide
- mechanism: block Na, K+2Cl- co transporter in thick ascending limb of Loop of Henle
- effect: use with edema, MOST EFFECT DIURETICS
- adverse effects: hyokalemia, decreased uric acid excretion, deafness
Aldosterone receptor blockers
- spironolactone & eplerenone
- mechanism: collecting duct; block Na+ & water reabsorption, K+ sparing
- use: resistant HTN, CHF HTN
- adverse effects: HYPERKALEMIA*** not hypo
Potassium sparing diuretics
- triameterene, amiloride
- mechanism: late distal tubule & collecting duct Na+ channel blockers
- diuretic effect in combo w/ thiazides: mild diuresis, weak HTN effect
- adverse effects: HYPERKALEMIA
RAS inhibitors & HTN
- blood levels of drugs & renin don’t correlate w/ effects
- non renal RAS: vascular & brain
- ACE/aldosterone escape: increased renin release, loss of negative feedback, RAAS and non RAAS mediated mechanism
Angiotensin II actions
- vasocontriction–increasing blood pressure
- stimulate thirst & secretion of aldosterone/ADH, increasing fluid/Na+
- increase SNS: increasing cardiac activity and PVR
- cardiac and vascular remodeling
- feedback inhibition of renin release
ACE inhibitors
- captopril, enalapril, lisinopril, fosinopril (PRILs)
- mechanism: block conversion of angiotensin I to II, elevate bradykinin levels, decreased PVR, decreased aldosterone (increasing Na+/water excretion), reverse or reduce CV remodeling, increase plasma renin & renin activity
ACE inhibitors: use & adverse effects
- use: mild/moderate HTN & heart failure
- adverse effects: DRY COUGH (20%), hyperkalemia, angioedema, hypotension, rash, pregnancy problems,
Angiotensin receptor antagonists (ARBs)
- losartan, valsartan, candesartan, irbesartan
- mehcanism: AT1 antagonist, vasodilation, increased Na+/water excretion, reduced plasma volume & cellular hypertrophy, increased plasma renin & renin activity
ARBs use and adverse effects
- use: HTN & heart failure
- adverse effects: hypotension, cough or angioedema but less than ACEIs (don’t start w/ this b/c don’t have as good long term effects, not used in combo w/ ACEIs), hyperkalemia, fetal renal toxicity
Renin inhibitor
- aliskiren
- mechanism: direct competitive inhibitor, increase plasma renin but NOT renin activity
- use: HTN (not first line since long term CV outcome unclear)
- adverse: diabetic/renal impairment, hypotension, dry cough, angioedema, hyperkalemia
Calcium channel blockers
- cardioselective: verapamil, diltiazem
- VSM selective: nifedipine, nicardipine, amplodipine (better for HTN)
- mechanism: block voltage L-type Ca2+ channels, relax VSM & decrease PVR, decrease MAP (reflec increase SNS & HR–THEREFORE COMBINED WITH BETA BLOCKER), negative chronotropic-verapamil, diltiazem
Calcium channel blockers (CCB) use & adverse effects
- use: HTN (low renin), AFRICAN AMERICAN & OLDER PATIENTS W/ SYSTOLIC HTN: DIHYDROPYRIDINES MORE EFFECTIVE
- adverse: contraindicated in heart failure (edema), depresses AV conduction/contractility, headache, gingival inflammation/hyperplasia
Drugs acting on SNS
- site of action: beta/alpha-adrenergic receptor antagonists, inhibitors of peripheral adrenergic transmission, central mediated anti hypertensives
B-adrenergic receptor antagonists
- B1 & B2: propranolol; B1: meoprolol, atenolol
- mechanism: decreased CO, renin secretion
- use: alone or in combo for HTN
- adverse: nausea, vomiting, confusion, dizziness, fatigue, SLEEP DISORDERS-lipophilic propranolol
When to avoid using B-blockers
- asthmatics or peripheral vascular disease
- diabetic: inability to elevate glucose
- promote development of type 2 diabetes
- *withdrawal: rebound HTN**
A-adrenergic receptor antagonists
- prazosin, doxazosin
- mechanism: block a1 receptors on VSM, dilation of arterioles
- use: alone or in combo for HTN (PHEOCHROMOCYTOMA)
- adverse: reflect tachycardia, orthostatic hypotension, fluid retention, GI upset, palpitation, tinnitus, headache, dizziness, urinary incontinence
- *water retention-use with diuretic or B-antagonist**
Alpha & Beta adrenergic antagonists
- labetalol: mix of four stereoisomers, use: chronic HTN & HTN emergencies
- carvedilol: antioxidant & antiproliferative, use: HTN & heart failure
Inhibitors of adrenergic transmission
- mechanism: deplete NE from adrenergic nerve endings, inhibits reuptake of NE, decrease PVR and CO
- use: HTN, resurgence in use, combine w/ thiazide diuretic
- adverse: postural hypotension, sedation, dry mouth, nightmares, Na+/water retention–this is why you add diuretic
Central mediated anti hypertensives
- clonidine, alpha-methyldopa (prodrug)
- mechanism: stimulate brainstem a2 receptors (decreased SNS outflow), vagal activity to heart increased, decreased, PVR & CO
- use: resistant HTN–conidine, pregnancy induced HTN–methyldopa
- adverse: rebound HTN, sedation, dry mouth, depression, drowsiness, Na+/water retention–add diuretic, postural hypotension in elderly
Vasodilators
- hydralazine, minoxidil, nitroprusside, riociguat, nitroglycerin, epoprostenol, bosentan, ambrisentan
- mehcanism: direct dilators of VSM, decrease PVR, BARORECEPTOR ACTIVATION (THERFORE USE WITH DIURETICS & B-ANTAGONISTS)
Hydralazine
- vasodilator: reduced intracellular calcium, ARTERIOLES, decreased PVR/MAP, reflex increase in HR, contractility, CO**
- use: HTN in combo w/ diuretic & B-blocker
- adverse: headache, anorexia, nausea, dizziness, sweating, angina or ischemic arrhythmias w/ ischemic heart disease due to reflex tachycardia, increased renin/fluid retention, IMMUNE RESPONSE: LUPUS
Minoxidil
- vasodilator: ARTERIOLES, decreased PVR, activated K+ channels (VSM relaxation), reflex increase in HR, contractility, CO
- use: resistant HTN in combo with diuretic & B-blocker
- adverse: fluid retention: contraindicated in HF, pericardial effusion and cardiac tamponade, reflex tachycardia, ABNORMAL HAIR GROWTH (topical use for alopecia)**
Nitroprusside
- vasodilator: direct vasodilator, generates NO, effects VEINS & ARTERIES to reduce preload/afterload
- use: produce HYPOtension in surgery & HYPERTENSIVE emergency
- adverse: rapid decrease in MAP, cyanide accumulation (infusions>48hrs and/or impaired renal function)
Nitroglycerin
- vasodilator: VEINS, generates NO
- use: HYPOtension in surgery, HTN emergencies
- pharmacokinetics: short duration of action, tolerance
- adverse: headaches indicates that drug is working
Epoprosterol
- vasodilator: prostacyclin (PGI2)
- mechanism: direct vasodilator via cAMP, counteracts TXA2
- use: potent antihypertensive must be administered CONTINUOUSLY
- USED FOR PRIMARY PULMONARY HYPERTENSION*
Endothelin receptor blockers
- nonselective: bosentan, ETa receptor blocker: ambrisentan
- use: PULMONARY HTN
- adverse: edema, headache, spermatogenesis inhibition, respiratory tract infection, decreased hematocrit, hepatic effects
- *VASODILATORS**
Riociguat
- vasodilator: directly stimulates guanylyl cyclase, increases cGMP
- use: pulmonary HTN, thromboembolic pulmonary HTN, combine w/ ET receptor blockers
- adverse: headache, dizziness, nausea, diarrhea, hypotension, BIRTH DEFECTS
Stage 1 HTN treatment
- monotherapy: ACE inhibitor, ARB, CCB, thiazide diuretic or two dug combo
Stage 2 HTN treatment
- TWO DRUG COMBO
- ACE inhibitor or ARB w/ thiazide diuretic or ARB w/ CCB
Pharmacological approach
- monotherapy vs. combination therapy
- advantages of combined therapy: different classes w/ complementary actions, lower dose, fewer side effects, improved compliance